Back

Catheter ablation for atrial fibrillation in patients with cardiac amyloidosis - Clinical characteristics and outcomes

13 April 2026 (10:30 - 11:15)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation nonmodifiable risk factors Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Mrs Maru Mronz

Heart Center at the University of Cologne, Cologne (Germany)

5 More presentations in this session

Presentation thumbnail
Creating a pipeline to extract genetic variants associated with atrial fibrillation to use in large, multi-ethnic management registries
Ms E. Dave (Downers Grove, US)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation in adults under 40 years: clinical profile, management strategies, and long-term outcomes after catheter ablation
Doctor A. Bakytzhanuly (Astana, KZ)
Abstract Slides Video
Presentation thumbnail
Impact of atrial fibrillation on the prevalence and characteristics of cytopenia and clonal cytopenia of undetermined significance
Ms C. Forner (Luebeck, DE)
Abstract Slides Video
Presentation thumbnail
Atrial fibrillation burden according to genetic risk: a secondary analysis of the randomised LOOP study
Mr J. Baadsgaard (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Sex differences after atrial fibrillation ablation: a patient level meta-analysis
Mr L. Barbosa (Belo Horizonte, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation nonmodifiable risk factors

The Event

Event poster

EHRA 2026

13 April 2026 10:30 CET
You may be interested in
thumbnail
Congress Presentation
Safety and efficacy of catheter ablation in patients with atrial arrhythmias and cardiac amyloidosis: a systematic review and meta-analysis
thumbnail
Congress Presentation
Substrate characterization and outcomes of ventricular tachycardia ablation in amyloid cardiomyopathy: a worldwide study
thumbnail
Congress Presentation
Reduced heart failure hospitalizations and improved quality of life in cardiac amyloidosis patients undergoing atrial fibrillation ablation

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources